Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Archie Meeties who wrote (14508)	12/5/2004 11:38:39 AM
From: scaram(o)uche	Read Replies (1) of 52153

I went to Dr. Hacksell's presentation, 10/13, at the BioEmerging Company Forum. I don't remember any discussion of agranulocytosis. May have been one, but I don't remember it. There was mention that they expect avoidance of weight gain, but I used "grain of salt" filter. The Allergan project (neuropathic pain) sounds hot. Huge under-served market, and the recent IND was the first of two (that is, there's a second molecule coming down the pipe). Glaucoma (AC-262271) isn't a tiny market either. Harry.... no enthusiasm for "103"? I'll take further discussion to the company-specific thread.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next